AzTrials
AzTrials

Endometrial CancerPhase 3TroFuse-033NCT06952504

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

A Phase 3 study testing Pembrolizumab, Carboplatin and Paclitaxel in people with Endometrial Cancer, run by Merck Sharp & Dohme LLC at 268 sites in 34 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. EC is a type of cancer that starts in the tissues inside the uterus (womb) pMMR indicates that certain normal proteins are present in the cancer cells Advanced means the… Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Endometrial Cancer
What is being tested?
Pembrolizumab, Carboplatin and Paclitaxel
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,123 participants
Where
268 sitesin 34 countries
Study dates
22 May 2025to 24 May 2032
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Has a histologically confirmed diagnosis of primary advanced or recurrent endometrial carcinoma that has been confirmed as proficient mismatch repair (pMMR)
  • Has radiographically evaluable disease, with measurable Stage III or either measurable or non-measurable Stage IV or recurrent disease per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1), as assessed by the investigator
  • Has received no prior systemic therapy for endometrial carcinoma except the following conditions as pre-specified by the protocol: 1 prior line of systemic platinum-based adjuvant and/or neoadjuvant chemotherapy in the setting of curative-intent, prior radiation with or without radiosensitizing chemotherapy if >2 weeks before the start of induction treatment, or prior hormonal therapy for treatment of endometrial carcinoma that was discontinued ≥1 week before the start of induction treatment

Who cannot join

  • Has carcinosarcoma, neuroendocrine tumors or endometrial sarcoma, including stromal sarcoma, leiomyosarcoma, adenosarcoma, or other types of sarcomas
  • Has endometrial carcinoma of any histology that is mismatch repair deficient (dMMR)
  • Is a candidate for debulking surgery resulting in complete removal of all tumor and no evidence of radiological disease following surgery, or curative-intent radiotherapy at the time of enrollment
  • Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
  • Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
  • Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
  • Human Immunodeficiency Virus-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Received prior therapy in any setting with any of the following: anti-programmed cell death 1 protein, anti-programmed cell death ligand 1, anti-programmed cell death ligand 2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor; trophoblast cell surface antigen 2-targeted antibody drug conjugate; or topoisomerase I inhibitor-containing antibody drug conjugate

Trial locations and contacts

268 sites in 34 countries. Contact the study team or a site near you to ask about taking part.

Toll Free Number contact

1-888-577-8839

Trialsites@msd.com

268 sites in 34 countries

United States53 sites, 52 recruiting

  • University of New Mexico Comprehensive Cancer Center ( Site 6046)

    Albuquerque, New Mexico, 87131

    Study Coordinator, 505-272-4946

    Recruiting

  • Alaska Women's Cancer Care ( Site 6036)

    Anchorage, Alaska, 99508

    Study Coordinator, 907-562-4673

    Recruiting

  • St. Luke's University Health Network ( Site 6041)

    Bethlehem, Pennsylvania, 18015

    Study Coordinator, 484-503-4673

    Recruiting

  • Tufts Medical Center ( Site 6052)

    Boston, Massachusetts, 02111

    Study Coordinator, 617-636-2616

    Recruiting

  • Miami Valley Hospital South ( Site 6014)

    Centerville, Ohio, 45459

    Study Coordinator, 937-438-7800

    Recruiting

  • Erlanger Medical Center ( Site 5009)

    Chattanooga, Tennessee, 37403

    Study Coordinator, 423-778-3902

    Recruiting

  • University of Chicago Medical Center ( Site 5002)

    Chicago, Illinois, 60637

    Study Coordinator, 773-702-1220

    Recruiting

  • University of Cincinnati Medical Center ( Site 5013)

    Cincinnati, Ohio, 45219

    Study Coordinator, 403-906-6222

    Recruiting

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007)

    Columbus, Ohio, 43210

    Study Coordinator, 614-293-9337

    Recruiting

  • Women's Cancer Care ( Site 6010)

    Covington, Louisiana, 70433

    Study Coordinator, 985-317-6005

    Recruiting

  • Duke Cancer Institute ( Site 6049)

    Durham, North Carolina, 27710

    Study Coordinator, 919-684-3780

    Recruiting

  • Oncology Associates of Oregon, P.C. ( Site 8005)

    Eugene, Oregon, 97401

    Study Coordinator, 541-736-3385

    Recruiting

  • Inova Schar Cancer Institute ( Site 6003)

    Fairfax, Virginia, 22031

    Study Coordinator, 571-472-4724

    Recruiting

  • Virginia Cancer Specialists (VCS) ( Site 8008)

    Fairfax, Virginia, 22031

    Study Coordinator, 703-280-5390

    Recruiting

  • Florida Cancer Specialists - South ( Site 7003)

    Fort Myers, Florida, 33901

    Study Coordinator, 239-274-9930

    Recruiting

  • Parkview Research Center ( Site 6008)

    Fort Wayne, Indiana, 46845

    Study Coordinator, 800-724-8326

    Recruiting

  • Texas Oncology - DFW ( Site 8004)

    Fort Worth, Texas, 76104

    Study Coordinator, 817-413-1500

    Recruiting

  • UF Health Davis Cancer Pavilion and Shands Med Plaza ( Site 6026)

    Gainesville, Florida, 32608

    Study Coordinator, 352-273-7832

    Recruiting

  • Houston Methodist Hospital ( Site 6057)

    Houston, Texas, 77030

    Study Coordinator, 713-441-6616

    Recruiting

  • CHAO Family Comprehensive Cancer Center and Ambulatory Care ( Site 5014)

    Irvine, California, 92612

    Study Coordinator, 714-456-8000

    Recruiting

  • St. Dominic's Hospital ( Site 5004)

    Jackson, Mississippi, 39216

    Study Coordinator, 601-200-4970

    Recruiting

  • Kettering Health Main Campus-Kettering Health Cancer Center ( Site 5001)

    Kettering, Ohio, 45429

    Study Coordinator, 937-395-6017

    Recruiting

  • Mount Sinai Braman Comprehensive Cancer Center ( Site 6031)

    Miami Beach, Florida, 33140

    Study Coordinator, 305-674-2625

    Recruiting

  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 6055)

    Mineola, New York, 11501

    Study Coordinator, 516-708-4821

    Recruiting

  • Minnesota Oncology Hematology, PA ( Site 8003)

    Minneapolis, Minnesota, 55404

    Study Coordinator, 817-837-8660

    Recruiting

  • University of South Alabama, Mitchell Cancer Institute ( Site 6033)

    Mobile, Alabama, 36604

    Study Coordinator, 251-665-8000

    Recruiting

  • Yale University School of Medicine ( Site 6009)

    New Haven, Connecticut, 06510

    Study Coordinator, 203-737-4450

    Recruiting

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6004)

    New York, New York, 10016

    Study Coordinator, 212-731-6455

    Recruiting

  • Memorial Sloan Kettering Cancer Center ( Site 6053)

    New York, New York, 10065

    Study Coordinator, 212-639-2000

    Recruiting

  • University of Oklahoma Health Sciences Center, Stephenson Cancer Center ( Site 6012)

    Oklahoma City, Oklahoma, 73104

    Study Coordinator, 855-750-2273

    Recruiting

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 6020)

    Orange, California, 92868

    Study Coordinator, 949-813-1517

    Recruiting

  • AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 6002)

    Orlando, Florida, 32804

    Study Coordinator, 407-609-3462

    Recruiting

  • Hospital of the University of Pennsylvania ( Site 5007)

    Philadelphia, Pennsylvania, 19104

    Study Coordinator, 215-662-2487

    Recruiting

  • Hospital of the University of Pennsylvania ( Site 6023)

    Philadelphia, Pennsylvania, 19104

    Completed

  • FirstHealth of the Carolinas ( Site 6037)

    Pinehurst, North Carolina, 28374

    Study Coordinator, 910-715-8684

    Recruiting

  • AHN West Penn Hospital ( Site 6006)

    Pittsburgh, Pennsylvania, 15224

    Study Coordinator, 412-578-1116

    Recruiting

  • Women & Infants Hospital ( Site 5003)

    Providence, Rhode Island, 02905

    Study Coordinator, 401-453-7520

    Recruiting

  • The Center of Hope ( Site 5018)

    Reno, Nevada, 89511

    Study Coordinator, 775-327-4673

    Recruiting

  • VCU Health Adult Outpatient Pavillion ( Site 5000)

    Richmond, Virginia, 23219

    Study Coordinator, 804-628-4368

    Recruiting

  • Texas Oncology-San Antonio Medical Center ( Site 8001)

    San Antonio, Texas, 78240

    Study Coordinator, 210-595-5300

    Recruiting

  • St. Joseph's/Candler Health System ( Site 6021)

    Savannah, Georgia, 31405

    Study Coordinator, 912-819-5704

    Recruiting

  • Maine Medical Center - Scarborough Campus ( Site 6042)

    Scarborough, Maine, 04074

    Study Coordinator, 207-396-7089

    Recruiting

  • TRIALS 365 ( Site 6005)

    Shreveport, Louisiana, 71103

    Study Coordinator, 318-408-1198

    Recruiting

  • Sansum Clinic (Ridley Tree) ( Site 8007)

    Solvang, California, 93463

    Study Coordinator, 805-879-0643

    Recruiting

  • Washington University - School of Medicine ( Site 5006)

    St Louis, Missouri, 63110

    Study Coordinator, 314-747-3604

    Recruiting

  • Florida Cancer Specialists ( Site 7002)

    St. Petersburg, Florida, 33701

    Study Coordinator, 727-522-0558

    Recruiting

  • Holy Name Medical Center ( Site 6011)

    Teaneck, New Jersey, 07666

    Study Coordinator, 201-227-6200

    Recruiting

  • Oklahoma Cancer Specialists and Research Institute, LLC ( Site 6047)

    Tulsa, Oklahoma, 74146

    Study Coordinator, 918-505-3200

    Recruiting

  • Texas Oncology - Northeast Texas ( Site 8002)

    Tyler, Texas, 75702

    Study Coordinator, 903-579-9800

    Recruiting

  • John Muir Health Cancer Center ( Site 6028)

    Walnut Creek, California, 94598

    Study Coordinator, 925-674-2580

    Recruiting

  • MedStar Washington Hospital Center ( Site 5005)

    Washington D.C., District of Columbia, 20010

    Study Coordinator, 202-877-7000

    Recruiting

  • Texas Oncology - Gulf Coast ( Site 8006)

    Webster, Texas, 77598

    Study Coordinator, 281-332-7505

    Recruiting

  • Florida Cancer Specialists East ( Site 7001)

    West Palm Beach, Florida, 33401

    Study Coordinator, 561-366-4100

    Recruiting

Other trials in United States

China33 sites, 33 recruiting

  • Peking University Peoples Hospital ( Site 0845)

    Beijing, Beijing Municipality, 100044

    Study Coordinator, (010) 8832 5988

    Recruiting

  • The First Hospital Of Jilin University ( Site 0815)

    Changchun, Jilin, 134021

    Study Coordinator, 0431-88782222

    Recruiting

  • Xiangya Hospital Central South University ( Site 0821)

    Changsha, Hunan, 410008

    Study Coordinator, 0731-89753999

    Recruiting

  • Hunan Cancer Hospital ( Site 0826)

    Changsha, Hunan, 410013

    Study Coordinator, 0731-88651900

    Recruiting

  • West China Second University Hospital, Sichuan University ( Site 0849)

    Chengdu, Sichuan, 610000

    Study Coordinator, 028-85503776

    Recruiting

  • Chongqing University Cancer Hospital ( Site 0838)

    Chongqing, Chongqing Municipality, 400030

    Study Coordinator, +8602365311341

    Recruiting

  • Fujian Province Cancer Hospital ( Site 0802)

    Fuzhou, Fujian, 350014

    Study Coordinator, 0591-83660063

    Recruiting

  • Sun Yat-sen University Cancer Center ( Site 0846)

    Guangzhou, Guangdong, 510060

    Study Coordinator, +86-020-87343272

    Recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University ( Site 0801)

    Guangzhou, Guangdong, 510220

    Study Coordinator, 020-81332736

    Recruiting

  • Zhujiang Hospital of Southern Medical University ( Site 0829)

    Guangzhou, Guangdong, 510280

    Study Coordinator, +86-020-61643888

    Recruiting

  • The Affiliated Women's Hospital of Zhejiang University ( Site 0834)

    Hangzhou, Zhejiang, 310006

    Study Coordinator, 0571-87061501

    Recruiting

  • Harbin Medical University Cancer Hospital ( Site 0850)

    Harbin, Heilongjiang, 150000

    Study Coordinator, 0451-86298000

    Recruiting

  • Anhui Provincial Hospital ( Site 0830)

    Hefei, Anhui, 230001

    Study Coordinator, 0551-62283666

    Recruiting

  • Shandong Cancer Hospital ( Site 0803)

    Jinan, Shandong, 250117

    Study Coordinator, 0531-87984777

    Recruiting

  • Yunnan Province Cancer Hospital ( Site 0811)

    Kunming, Yunnan, 650118

    Study Coordinator, 0871-68103376

    Recruiting

  • Taizhou Hospital of Zhejiang Province ( Site 0809)

    Linhai, Zhejiang, 317000

    Study Coordinator, 0576-85199810

    Recruiting

  • LinYi Cancer Hospital ( Site 0820)

    Linyi, Shandong, 276034

    Study Coordinator, 13583991399

    Recruiting

  • Liuzhou People's Hospital ( Site 0831)

    Liuzhou, Guangxi, 545006

    Study Coordinator, +86772-3612345

    Recruiting

  • Jiangxi Maternal and Child Health Hospital ( Site 0807)

    Nanchang, Jiangxi, 337000

    Study Coordinator, 0791-82725189

    Recruiting

  • Nanjing First Hospital ( Site 0828)

    Nanjing, Jiangsu, 210006

    Study Coordinator, 025-52271000

    Recruiting

  • Guangxi Medical University Affiliated Tumor Hospital. ( Site 0825)

    Nanning, Guangxi, 530021

    Study Coordinator, +8607715778582

    Recruiting

  • Shanghai Tenth People's Hospital ( Site 0847)

    Shanghai, Shanghai Municipality, 200072

    Study Coordinator, 021-66300588

    Recruiting

  • Obstetrics & Gynecology Hospital of Fudan University ( Site 0818)

    Shanghai, Shanghai Municipality, 200090

    Study Coordinator, 021-33189900

    Recruiting

  • Cancer Hospital of Shantou University Medical College ( Site 0827)

    Shantou, Guangdong, 515041

    Study Coordinator, +8675488555844

    Recruiting

  • Shanxi Provincial Cancer Hospital ( Site 0843)

    Taiyuan, Shanxi, 030013

    Study Coordinator, (0351) 465 1590

    Recruiting

  • The First Affiliated Hospital of Wenzhou Medical University ( Site 0805)

    Wenzhou, Zhejiang, 325015

    Study Coordinator, 0577-55579590

    Recruiting

  • Wuhan Union Hospital Cancer Center ( Site 0824)

    Wuhan, Hubei, 430023

    Study Coordinator, 027-85726114

    Recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University ( Site 0816)

    Xi'an, Shaanxi, 710061

    Study Coordinator, 029-85323840

    Recruiting

  • The First Affiliated hospital of Xiamen University ( Site 0822)

    Xiamen, Fujian, 361003

    Study Coordinator, 0592-2130789

    Recruiting

  • The Second People's Hospital of Yibin ( Site 0840)

    Yibin, Sichuan, 644000

    Study Coordinator, 0831 888 8120

    Recruiting

  • Affiliated Hospital of Guangdong Medical University ( Site 0823)

    Zhanjiang, Guangdong, 524004

    Study Coordinator, 07592369367

    Recruiting

  • Henan Cancer Hospital ( Site 0806)

    Zhengzhou, Henan, 450008

    Study Coordinator, 0371-65587418

    Recruiting

  • The Second Affiliated Hospital of Zhengzhou University ( Site 0833)

    Zhengzhou, Henan, 450014

    Study Coordinator, 0371-63974853

    Recruiting

Other trials in China

Japan18 sites, 18 recruiting

  • Hyogo Cancer Center ( Site 2216)

    Akashi, Hyōgo, 673-8558

    Study Coordinator, +81-78-929-1151

    Recruiting

  • National Cancer Center Hospital ( Site 2211)

    Chūō, Tokyo, 104-0045

    Study Coordinator, +81-3-3542-2511

    Recruiting

  • National Hospital Organization Kyushu Cancer Center ( Site 2203)

    Fukuoka, 811-1395

    Study Coordinator, +81-92-541-3231

    Recruiting

  • Fukushima Medical University Hospital ( Site 2218)

    Fukushima, 960-1295

    Study Coordinator, +81-24-547-1772

    Recruiting

  • Saitama Medical University International Medical Center ( Site 2201)

    Hidaka, Saitama, 350-1298

    Study Coordinator, +81-42-984-4111

    Recruiting

  • Cancer Institute Hospital of JFCR ( Site 2208)

    Koto, Tokyo, 135-8550

    Study Coordinator, +81-3-3520-0111

    Recruiting

  • Kurume University Hospital ( Site 2204)

    Kurume, Fukuoka, 830-0011

    Study Coordinator, +81-942-35-3311

    Recruiting

  • National Hospital Organization Shikoku Cancer Center ( Site 2206)

    Matsuyama, Ehime, 791-0280

    Study Coordinator, +81-89-999-1111

    Recruiting

  • Aichi Cancer Center ( Site 2217)

    Nagoya, Aichi-ken, 464-8681

    Study Coordinator, +81-52-762-6111

    Recruiting

  • Niigata Cancer Center Hospital ( Site 2210)

    Niigata, 951-8566

    Study Coordinator, +81-25-266-5111

    Recruiting

  • Okayama University Hospital ( Site 2215)

    Okayama, 700-8558

    Study Coordinator, +81-86-223-7151

    Recruiting

  • Gunma Prefectural Cancer Center ( Site 2202)

    Ōta, Gunma, 373-8550

    Study Coordinator, +81-276-38-0771

    Recruiting

  • National Hospital Organization Hokkaido Cancer Center ( Site 2212)

    Sapporo, Hokkaido, 003-0804

    Study Coordinator, +81-11-811-9111

    Recruiting

  • Keio University Hospital ( Site 2209)

    Shinjuku, Tokyo, 160-8582

    Study Coordinator, +81-3-3353-1211

    Recruiting

  • Iwate Medical University Hospital ( Site 2207)

    Shiwa-gun, Iwate, 028-3695

    Study Coordinator, +81-19-613-7111

    Recruiting

  • Shizuoka Cancer Center ( Site 2205)

    Sunto-gun, Shizuoka, 411-8777

    Study Coordinator, +81-55-989-5222

    Recruiting

  • Ehime University Hospital ( Site 2213)

    Tōon, Ehime, 791-0295

    Study Coordinator, +81-89-964-5111

    Recruiting

  • Yamagata University Hospital ( Site 2219)

    Yamagata, 990-9585

    Study Coordinator, +81-23-628-5840

    Recruiting

Other trials in Japan

Canada14 sites, 14 recruiting

  • Royal Victoria Regional Health Centre ( Site 0615)

    Barrie, Ontario, L4M 6M2

    Study Coordinator, 705 728-9090x66228

    Recruiting

  • London Health Sciences Centre ( Site 0611)

    London, Ontario, N6A 5W9

    Study Coordinator, 519-685-8500

    Recruiting

  • CIUSSS de l'Est-de-l'Île-de-Montréal ( Site 0607)

    Montreal, Quebec, H1T 2M4

    Study Coordinator, 514-252-3400 X5766

    Recruiting

  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0605)

    Montreal, Quebec, H2X 0C1

    Study Coordinator, 514-890-8000 x30777

    Recruiting

  • Jewish General Hospital ( Site 0606)

    Montreal, Quebec, H3T 1E2

    Study Coordinator, 514-340-8222

    Recruiting

  • McGill University Health Centre ( Site 0604)

    Montreal, Quebec, H4A 3J1

    Study Coordinator, 5145772241

    Recruiting

  • Sault Area Hospital ( Site 0616)

    Sault Ste. Marie, Ontario, P6B 0A8

    Study Coordinator, 705-759-3434x4402

    Recruiting

  • CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0608)

    Sherbrooke, Quebec, J1H 5N4

    Study Coordinator, 8193461110x12890

    Recruiting

  • NL Health Services ( Site 0602)

    St. John's, Newfoundland and Labrador, A1B 3V6

    Study Coordinator, 709-777-6300

    Recruiting

  • BC Cancer Surrey ( Site 0621)

    Surrey, British Columbia, V3V 1Z2

    Study Coordinator, 604-930-2098

    Recruiting

  • Sunnybrook Research Institute ( Site 0610)

    Toronto, Ontario, M4N 3M5

    Study Coordinator, 416 480-6100

    Recruiting

  • Princess Margaret Cancer Center ( Site 0609)

    Toronto, Ontario, M5G 2M9

    Study Coordinator, 416-946-4501

    Recruiting

  • Windsor Regional Cancer Program ( Site 0614)

    Windsor, Ontario, N8W 1L9

    Study Coordinator, 519-254-5577

    Recruiting

  • CancerCare Manitoba ( Site 0617)

    Winnipeg, Manitoba, R3E 0V9

    Study Coordinator, 204-787-4156

    Recruiting

Other trials in Canada

Italy13 sites, 13 recruiting

  • Ospedale Cannizzaro ( Site 2103)

    Catania, 95126

    Study Coordinator, +39-0957262083

    Recruiting

  • Azienda Ospedaliera Universitaria Careggi ( Site 2109)

    Florence, 50134

    Study Coordinator, +39-0557947908

    Recruiting

  • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 2107)

    Meldola, Forli-Cesena, 47014

    Study Coordinator, +39-0543739968

    Recruiting

  • Ospedale Humanitas San Pio X ( Site 2106)

    Milan, Lombardy, 20159

    Study Coordinator, +39-0269517533

    Recruiting

  • Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 2114)

    Milan, 20133

    Study Coordinator, +39-0223902719

    Recruiting

  • Istituto Europeo di Oncologia ( Site 2110)

    Milan, 20141

    Study Coordinator, +39-0294372732

    Recruiting

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 2104)

    Naples, 80131

    Study Coordinator, +39-0815903637

    Recruiting

  • Azienda Ospedaliero Universitaria Pisana Ospedale S. Chiara ( Site 2108)

    Pisa, 56126

    Study Coordinator, +39-050992371

    Recruiting

  • Istituto Nazionale Tumori Regina Elena ( Site 2102)

    Roma, 00 128

    Study Coordinator, +39-0652666771

    Recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli ( Site 2105)

    Roma, 00168

    Study Coordinator, +39-0630154994

    Recruiting

  • Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino ( Site 2111)

    Torino, 10126

    Study Coordinator, +39-0113131523

    Recruiting

  • Ospedale Mauriziano ( Site 2101)

    Torino, 10128

    Study Coordinator, +390115082046

    Recruiting

  • Ospedale Santa Maria di Ca' Foncello ( Site 2112)

    Treviso, 31100

    Study Coordinator, +39-0422322051

    Recruiting

Other trials in Italy

United Kingdom11 sites, 11 recruiting

  • Addenbrookes Hospital ( Site 4002)

    Cambridge, Cambridgeshire, CB2 0QQ

    Study Coordinator, +441223805000

    Recruiting

  • University Hospitals Sussex NHS Foundation Trust ( Site 4011)

    East Sussex, Brighton And Hove, BN2 1ES

    Study Coordinator, 01273696955

    Recruiting

  • Western General Hospital ( Site 4012)

    Edinburgh, Midlothian, EH4 2XU

    Study Coordinator, +441315371000

    Recruiting

  • The Beatson West of Scotland Cancer Centre ( Site 4004)

    Glasgow, Glasgow City, G12 0YN

    Study Coordinator, (0) 141 301 7207

    Recruiting

  • Leicester Royal Infirmary ( Site 4008)

    Leicester, LE1 5WW

    Study Coordinator, +443003031573

    Recruiting

  • University College London Hospital ( Site 4001)

    London, London, City of, NW1 2PG

    Study Coordinator, +442034477807

    Recruiting

  • ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 4006)

    London, London, City of, SW3 6JJ

    Study Coordinator, 02073528171

    Recruiting

  • Hammersmith Hospital ( Site 4010)

    London, London, City of, W12 0HS

    Study Coordinator, +443000330333

    Recruiting

  • Royal Marsden Hospital (Sutton) ( Site 4005)

    London, Surrey, SM3 5PT

    Study Coordinator, 02073528171

    Recruiting

  • Maidstone Hospital ( Site 4007)

    Maidstone, ME16 9QQ

    Study Coordinator, +441622729000

    Recruiting

  • The Christie NHS Foundation Trust ( Site 4003)

    Manchester, M20 4BX

    Study Coordinator, +441614463000

    Recruiting

Other trials in United Kingdom

France10 sites, 10 recruiting

  • Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest ( Site 1405)

    Bordeaux, Gironde, 33076

    Study Coordinator, +33556333333

    Recruiting

  • Centre Francois Baclesse ( Site 1412)

    Caen, Calvados, 14000

    Study Coordinator, +33231455002

    Recruiting

  • CENTRE LEON BERARD ( Site 1401)

    Lyon, Rhone, 69008

    Study Coordinator, +33478782716

    Recruiting

  • Institut Paoli Calmettes ( Site 1410)

    Marseille, Bouches-du-Rhone, 13272

    Study Coordinator, +33491223847

    Recruiting

  • Groupe Hospitalier Diaconesses Croix Saint Simon ( Site 1409)

    Paris, 75020

    Study Coordinator, +33144741013

    Recruiting

  • Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 1411)

    Paris, 75679

    Study Coordinator, +33158411439

    Recruiting

  • Hôpital Privé Des Côtes d'Armor ( Site 1404)

    Plérin, Cotes-d Armor, 22190

    Study Coordinator, +33296752216

    Recruiting

  • Institut Curie - site Saint-Cloud ( Site 1408)

    Saint-Cloud, Hauts-de-Seine, 92210

    Study Coordinator, +33147111549

    Recruiting

  • Institut De Cancerologie De L Ouest ( Site 1403)

    Saint-Herblain, Loire-Atlantique, 44800

    Study Coordinator, +33240679900

    Recruiting

  • LBM ONCOPOLE CLAUDIUS REGAUD ( Site 1407)

    Toulouse, Haute-Garonne, 31059

    Study Coordinator, +33531155101

    Recruiting

Other trials in France

Poland8 sites, 8 recruiting

  • Bialostockie Centrum Onkologii ( Site 3007)

    Bialystok, Podlaskie Voivodeship, 15-027

    Study Coordinator, 48856646732

    Recruiting

  • Uniwersyteckie Centrum Kliniczne-Klinika Ginekologii, Ginekologii Onkologicznej i Endokrynologii Gi ( Site 3001)

    Gdansk, Pomeranian Voivodeship, 80-214

    Study Coordinator, +48585844050

    Recruiting

  • Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 3006)

    Gliwice, Silesian Voivodeship, 44-101

    Study Coordinator, +48322788613

    Recruiting

  • Swietokrzyskie Centrum Onkologii. ( Site 3008)

    Kielce, Świętokrzyskie Voivodeship, 25-734

    Study Coordinator, +48885997850

    Recruiting

  • Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 3011)

    Poznan, Greater Poland Voivodeship, 60-569

    Study Coordinator, +48618549014

    Recruiting

  • Wielkopolskie Centrum Onkologii im. Marii Skłodowskiej-Curie ( Site 3003)

    Poznan, Greater Poland Voivodeship, 61-866

    Study Coordinator, +48 61 88 50 738

    Recruiting

  • Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 3004)

    Siedlce, Masovian Voivodeship, 08-110

    Study Coordinator, 256403070

    Recruiting

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 3002)

    Warsaw, Masovian Voivodeship, 02-781

    Study Coordinator, 225462268

    Recruiting

Other trials in Poland

Spain8 sites, 8 recruiting

  • Hospital Universitari Vall d''Hebron ( Site 3401)

    Barcelona, 08035

    Study Coordinator, +34934894350

    Recruiting

  • Hospital Universitario Reina Sofia ( Site 3402)

    Córdoba, 14004

    Study Coordinator, +34957011464

    Recruiting

  • Institut Català d'Oncologia (ICO) - Girona ( Site 3407)

    Girona, Gerona, 17007

    Study Coordinator, +34972225834

    Recruiting

  • Institut Català d'Oncologia - L'Hospitalet ( Site 3408)

    L'Hospitalet de Llobregat, Barcelona, 08908

    Study Coordinator, +34932607744

    Recruiting

  • Hospital Universitario Ramon y Cajal ( Site 3403)

    Madrid, 28034

    Study Coordinator, +34913368263

    Recruiting

  • Hospital Universitario 12 de Octubre ( Site 3404)

    Madrid, 28041

    Study Coordinator, +34913908003

    Recruiting

  • Hospital Universitario La Paz ( Site 3406)

    Madrid, 28046

    Study Coordinator, +34679927508

    Recruiting

  • Fundación Instituto Valenciano de Oncología ( Site 3405)

    Valencia, 46009

    Study Coordinator, +34961114249

    Recruiting

Other trials in Spain

Germany7 sites, 7 recruiting

  • Universitaetsklinikum Aachen ( Site 1507)

    Aachen, North Rhine-Westphalia, 52074

    Study Coordinator, +492418080700

    Recruiting

  • Charité Campus Virchow-Klinikum ( Site 1501)

    Berlin, 13353

    Study Coordinator, +49 30 450 564 404

    Recruiting

  • Asklepios Kliniken Hamburg ( Site 1509)

    Hamburg, 22307

    Study Coordinator, +49401818828138

    Recruiting

  • Universitaetsklinikum Jena ( Site 1503)

    Jena, Thuringia, 07747

    Study Coordinator, +49 3641 9329155

    Recruiting

  • Universitaetsklinikum Leipzig ( Site 1505)

    Leipzig, Saxony, 04103

    Study Coordinator, +49 341 97 23260

    Recruiting

  • CaritasKlinikum Saarbruecken St. Theresia ( Site 1508)

    Saarbrücken, Saarland, 66113

    Study Coordinator, +496814061301

    Recruiting

  • Klinikum Mutterhaus der Borromäerinnen ( Site 1506)

    Trier, Rhineland-Palatinate, 54290

    Study Coordinator, +4965194782635

    Recruiting

Other trials in Germany

South Korea6 sites, 6 recruiting

  • Keimyung University Dongsan Hospital ( Site 3105)

    Daegu, Taegu-Kwangyokshi, 42601

    Study Coordinator, +82532586679

    Recruiting

  • National Cancer Center ( Site 3106)

    Gyeonggi-do, Kyonggi-do, 10408

    Study Coordinator, +82319202591

    Recruiting

  • Seoul National University Hospital ( Site 3102)

    Seoul, 03080

    Study Coordinator, +82220723511

    Recruiting

  • Severance Hospital, Yonsei University Health System ( Site 3101)

    Seoul, 03722

    Study Coordinator, +82222282250

    Recruiting

  • Asan Medical Center ( Site 3103)

    Seoul, 05505

    Study Coordinator, +82230103748

    Recruiting

  • Samsung Medical Center ( Site 3104)

    Seoul, 06351

    Study Coordinator, +82234101382

    Recruiting

Other trials in South Korea

Argentina5 sites, 5 recruiting

  • Fundación Respirar ( Site 0101)

    Buenos Aires, Buenos Aires F.D., C1426AAL

    Study Coordinator, +541147815331

    Recruiting

  • Hospital Británico de Buenos Aires ( Site 0103)

    CABA, C1280AEB

    Study Coordinator, +541143096400

    Recruiting

  • Instituto Alexander Fleming ( Site 0105)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, C1426ANZ

    Study Coordinator, +5491166936669

    Recruiting

  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0108)

    Mar del Plata, Buenos Aires, B7600FZO

    Study Coordinator, +542234963223

    Recruiting

  • Instituto San Marcos ( Site 0106)

    San Juan, J5400EBB

    Study Coordinator, +542645836798

    Recruiting

Other trials in Argentina

Belgium5 sites, 5 recruiting

  • CHU Saint-Pierre ( Site 0405)

    Brussels, Bruxelles-Capitale, Region de, 1000

    Study Coordinator, +3225353534

    Recruiting

  • Grand Hôpital de Charleroi ( Site 0403)

    Charleroi, Wallonne, Region, 6060

    Study Coordinator, +32 60 11 25 00

    Recruiting

  • AZ Maria Middelares ( Site 0402)

    Ghent, Oost-Vlaanderen, 9000

    Study Coordinator, +3292469522

    Recruiting

  • UZ Leuven ( Site 0401)

    Leuven, Vlaams-Brabant, 3000

    Study Coordinator, +32 16 342 996

    Recruiting

  • CHU de Liege ( Site 0404)

    Liège, Wallonne, Region, 4000

    Study Coordinator, +3243237688

    Recruiting

Other trials in Belgium

Brazil5 sites, 5 recruiting

  • Hospital Araújo Jorge ( Site 0521)

    Goiânia, Goiás, 74605-070

    Study Coordinator, +55 62 3243-7260

    Recruiting

  • Liga Norte Riograndense Contra o Câncer ( Site 0523)

    Natal, Rio Grande do Norte, 59062-000

    Study Coordinator, +558440095595

    Recruiting

  • Hospital São Lucas da PUCRS ( Site 0522)

    Porto Alegre, Rio Grande do Sul, 90610-000

    Study Coordinator, +555133203000

    Recruiting

  • Instituto Nacional de Câncer - INCA ( Site 0515)

    Rio de Janeiro, 20220-410

    Study Coordinator, +552132072985

    Recruiting

  • IBCC - Instituto Brasileiro de Controle do Câncer ( Site 0525)

    São Paulo, São Paulo, 04014-002

    Study Coordinator, +551134744278

    Recruiting

Other trials in Brazil

Chile5 sites, 5 recruiting

  • Centro de Estudios Clínicos SAGA ( Site 0708)

    Santiago, Region M. de Santiago, 7500653

    Study Coordinator, +56991612199

    Recruiting

  • Fundación Arturo López Pérez ( Site 0702)

    Santiago, Region M. de Santiago, 7500921

    Study Coordinator, +569 97015608

    Recruiting

  • Pontificia Universidad Catolica de Chile ( Site 0705)

    Santiago, Region M. de Santiago, 8330032

    Study Coordinator, +56942477513

    Recruiting

  • Bradfordhill ( Site 0703)

    Santiago, Region M. de Santiago, 8420383

    Study Coordinator, +56229490970

    Recruiting

  • ONCOCENTRO APYS ( Site 0704)

    Viña del Mar, Valparaiso, 2520598

    Study Coordinator, +56323320850

    Recruiting

Other trials in Chile

Greece5 sites, 5 recruiting

  • Alexandra General Hospital of Athens ( Site 1604)

    Athens, Attica, 115 28

    Study Coordinator, 0030 2132162543

    Recruiting

  • Aretaieio Hospital ( Site 1602)

    Athens, Attica, 115 28

    Study Coordinator, 0030 2107286444

    Recruiting

  • ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 1603)

    Chaïdári, Attica, 124 62

    Study Coordinator, 0030 2313301848

    Recruiting

  • Iaso Genera ( Site 1605)

    Marousi, Attica, 151 23

    Study Coordinator, 0030 2107286305

    Recruiting

  • Agios Loukas Clinic-DEPARTMENT OF ONCOLOGY ( Site 1601)

    Thessaloniki, Central Macedonia, 552 36

    Study Coordinator, 0030 2310390972

    Recruiting

Other trials in Greece

Israel5 sites, 5 recruiting

  • Rambam Health Care Campus ( Site 2025)

    Haifa, 3109601

    Study Coordinator, +972544850251

    Recruiting

  • Carmel Hospital ( Site 2023)

    Haifa, 3436212

    Study Coordinator, +972544817280

    Recruiting

  • Shaare Zedek Medical Center ( Site 2020)

    Jerusalem, 9103102

    Study Coordinator, 02-6555424

    Recruiting

  • Meir Medical Center. ( Site 2021)

    Kfar Saba, 4428164

    Study Coordinator, 97297471575

    Recruiting

  • Sourasky Medical Center ( Site 2022)

    Tel Aviv, 6423906

    Study Coordinator, 97236973494

    Recruiting

Other trials in Israel

Mexico5 sites, 5 recruiting

  • Centro de Investigación Oncológica Galerías SC ( Site 2405)

    Aguascalientes, 20124

    Study Coordinator, +52 449 689 0593

    Recruiting

  • Sitio Clínico UIS Chihuahua (Operadora Unidad de Investigación en Salud de Chihuahua SA de CV) ( Site 2406)

    Chihuahua City, 31203

    Study Coordinator, +526144372837

    Recruiting

  • CIO - Centro de Inmuno-Oncología de Occidente ( Site 2402)

    Guadalajara, Jalisco, 44630

    Study Coordinator, +523330447001

    Recruiting

  • Laboratorio de Patología Clínica del Hospital Universitario "Dr. José Eleuterio González" ( Site 2401)

    Monterrey, Nuevo León, 64460

    Study Coordinator, +5283464690

    Recruiting

  • Centro de Investigacion Clinica de Oaxaca ( Site 2404)

    Oaxaca City, Oaxaca, 68020

    Study Coordinator, +529516035559

    Recruiting

Other trials in Mexico

Taiwan5 sites, 5 recruiting

  • Taichung Veterans General Hospital ( Site 3703)

    Taichung, 40705

    Study Coordinator, 886-4-23592525

    Recruiting

  • National Cheng Kung University Hospital ( Site 3702)

    Tainan, 704

    Study Coordinator, +88662353535

    Recruiting

  • National Taiwan University Hospital ( Site 3701)

    Taipei, 10002

    Study Coordinator, 886-2-23123456

    Recruiting

  • Mackay Memorial Hospital ( Site 3704)

    Taipei, 10449

    Study Coordinator, +886 975835334

    Recruiting

  • Linkou Chang Gung Memorial Hospital ( Site 3705)

    Taoyuan, 333

    Study Coordinator, 886-3-3281200

    Recruiting

Other trials in Taiwan

Australia4 sites, 4 recruiting

  • Blacktown Hospital ( Site 0201)

    Blacktown, New South Wales, 2148

    Study Coordinator, +610298818000

    Recruiting

  • Royal Brisbane and Women's Hospital ( Site 0206)

    Brisbane, Queensland, 4029

    Study Coordinator, 0736478111

    Recruiting

  • Epworth Freemasons ( Site 0207)

    Melbourne, Victoria, 3002

    Study Coordinator, 0394171344

    Recruiting

  • Sir Charles Gairdner Hospital ( Site 0203)

    Nedlands, Western Australia, 6009

    Study Coordinator, +610864573333

    Recruiting

Other trials in Australia

Colombia4 sites, 4 recruiting

  • FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0902)

    Bogotá, Bogota D.C., 110131

    Study Coordinator, +573183662238

    Recruiting

  • Promotora Médica las Américas S.A ( Site 0904)

    Medellín, Antioquia, 050025

    Study Coordinator, +57 3007193097

    Recruiting

  • Fundacion Colombiana de Cancerología Clinica Vida ( Site 0905)

    Medellín, Antioquia, 050030

    Study Coordinator, +57 3147362301

    Recruiting

  • Oncologos Del Occidente ( Site 0907)

    Pereira, Risaralda Department, 660001

    Study Coordinator, +573187715522

    Recruiting

Other trials in Colombia

Czechia4 sites, 4 recruiting

  • Nemocnice AGEL Novy Jicin a.s. ( Site 1102)

    Nový Jičín, 741 01

    Study Coordinator, +420556773111

    Recruiting

  • Fakultni nemocnice Ostrava ( Site 1104)

    Ostrava, Ostrava Mesto, 708 52

    Study Coordinator, +420597371804

    Recruiting

  • Vseobecna fakultni nemocnice v Praze-Gynekologicko-porodnicka klinika 1.LF a VFN ( Site 1101)

    Prague, 128 08

    Study Coordinator, +420224967451

    Recruiting

  • Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 1103)

    Prague, 150 06

    Study Coordinator, +420224434756

    Recruiting

Other trials in Czechia

Denmark4 sites, 4 recruiting

  • Aalborg Universitetshospital, Syd ( Site 1203)

    Aalborg, North Denmark, 9000

    Study Coordinator, +45 97660000

    Recruiting

  • Aarhus Universitetshospital, Skejby ( Site 1205)

    Aarhus, Central Jutland, 8200

    Study Coordinator, +45 78450000

    Recruiting

  • Herlev and Gentofte Hospital ( Site 1202)

    Copenhagen, Capital Region, 2730

    Study Coordinator, +45 38683868

    Recruiting

  • Sjællands Universitetshospital Køge ( Site 1204)

    Koege, Region Sjælland, 4600

    Study Coordinator, +4556631500

    Recruiting

Other trials in Denmark

Finland4 sites, 4 recruiting

  • Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus) ( Site 1301)

    Helsinki, Uusimaa, 00029

    Study Coordinator, 358504286945

    Recruiting

  • Kuopion Yliopistollinen Sairaala ( Site 1304)

    Kuopio, Northern Savonia, 70029

    Study Coordinator, 358447172741

    Recruiting

  • Tampereen yliopistollinen sairaala ( Site 1303)

    Tampere, Pirkanmaa, 33520

    Study Coordinator, 358408484029

    Recruiting

  • Turku University Hospital-Department of Obstetrics and Gynecology ( Site 1302)

    Turku, Southwest Finland, 20520

    Study Coordinator, 358405465398

    Recruiting

Other trials in Finland

Ireland4 sites, 4 recruiting

  • Cork University Hospital ( Site 1903)

    Cork, T12 DC4A

    Study Coordinator, +353214920500

    Recruiting

  • St. Vincent's University Hospital ( Site 1902)

    Dublin, Dublin, D04 T6F4

    Study Coordinator, +35312214000

    Recruiting

  • Mater Misericordiae University Hospital ( Site 1904)

    Dublin, D07 R2WY

    Study Coordinator, +35318034831

    Recruiting

  • St. James's Hospital ( Site 1901)

    Dublin, D08 E9P6

    Study Coordinator, +35314103752

    Recruiting

Other trials in Ireland

Thailand4 sites, 4 recruiting

  • Ramathibodi Hospital. ( Site 3802)

    Bangkok, Bangkok, 10400

    Study Coordinator, +66822316889

    Recruiting

  • Faculty of Medicine Siriraj Hospital ( Site 3801)

    Bangkok, Bangkok, 10700

    Study Coordinator, +6624141914

    Recruiting

  • Maharaj Nakorn Chiang Mai Hospital ( Site 3804)

    Chiang Mai, 50200

    Study Coordinator, +66804964292

    Recruiting

  • Faculty of Medicine - Khon Kaen University ( Site 3803)

    Khon Kaen, 40002

    Study Coordinator, +6643363029

    Recruiting

Other trials in Thailand

Austria3 sites, 3 recruiting

  • Medizinische Universität Graz-Abteilung für Gynäkologie / Onkologie ( Site 0303)

    Graz, Styria, 8036

    Study Coordinator, +43316 385 81648

    Recruiting

  • Medizinische Universitaet Innsbruck-Univ.-Klinik f. Gynäkologie und Geburtshilfe ( Site 0301)

    Innsbruck, Tyrol, 6020

    Study Coordinator, 435050423051

    Recruiting

  • Medizinische Universität Wien - Allg. Gynaekologie & Gyn. Onkologie ( Site 0302)

    Vienna, 1090

    Study Coordinator, +4314040061030

    Recruiting

Other trials in Austria

Hungary3 sites, 3 recruiting

  • Semmelweis Egyetem Szuleszeti es Nogyogyaszati Klinika ( Site 1703)

    Budapest, 1088

    Study Coordinator, 06203522207

    Recruiting

  • Országos Onkológiai Intézet-Ngyógyászat ( Site 1702)

    Budapest, 1122

    Study Coordinator, +3612248600 Ext 3616

    Recruiting

  • Debreceni Egyetem Klinikai Kozpont-Szülészeti és Nőgyógyászati Klinika ( Site 1701)

    Debrecen, 4032

    Study Coordinator, 0652255705

    Recruiting

Other trials in Hungary

Norway3 sites, 3 recruiting

  • Stavanger Universitetssykehus ( Site 2703)

    Norway, Rogaland, 4011

    Study Coordinator, +4751518000

    Recruiting

  • Oslo universitetssykehus, Radiumhospitalet ( Site 2701)

    Oslo, 0379

    Study Coordinator, +4722934404

    Recruiting

  • Universitetssykehuset Nord-Norge HF ( Site 2702)

    Tromsø, Troms, 9038

    Study Coordinator, +4777626000

    Recruiting

Other trials in Norway

Peru3 sites, 1 recruiting

  • Clínica San Felipe ( Site 2804)

    Jesus Maria, Lima region, 15072

    Active, not recruiting

  • INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS ( Site 2805)

    Lima, 15038

    Study Coordinator, +5112016500 e3009

    Recruiting

  • IPOR Instituto Peruano de Oncología & Radioterapia ( Site 2803)

    San Isidro, Lima region, 15038

    Active, not recruiting

Other trials in Peru

Netherlands2 sites, 2 recruiting

  • Maastricht UMC+ ( Site 2501)

    Maastricht, Limburg, 6229 HX

    Study Coordinator, +31433876543

    Recruiting

  • Universitair Medisch Centrum Utrecht ( Site 2503)

    Utrecht, 3584 CX

    Study Coordinator, +31887556263

    Recruiting

Other trials in Netherlands

Singapore2 sites, 2 recruiting

  • National University Hospital ( Site 3202)

    Singapore, Central Singapore, 119074

    Study Coordinator, 67795555

    Recruiting

  • National Cancer Centre Singapore ( Site 3201)

    Singapore, Central Singapore, 168583

    Study Coordinator, +65-6436-8000

    Recruiting

Other trials in Singapore

Sweden2 sites, 2 recruiting

  • Skånes Universitetssjukhus Lund ( Site 3502)

    Lund, Skåne County, 22185

    Study Coordinator, +46171000

    Recruiting

  • Akademiska Sjukhuset ( Site 3501)

    Uppsala, Uppsala County, 751 85

    Study Coordinator, 0186110000

    Recruiting

Other trials in Sweden

Puerto Rico1 site, 1 recruiting

  • Puerto Rico Cancer Specialists Clinical Trials ( Site 4201)

    San Juan, 00917

    Study Coordinator, +7879452919

    Recruiting

Other trials in Puerto Rico

About this study

Official title: A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)

Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent.

  • EC is a type of cancer that starts in the tissues inside the uterus (womb)
  • pMMR indicates that certain normal proteins are present in the cancer cells
  • Advanced means the cancer has spread locally or to other parts of the body (metastatic) and cannot be removed with surgery
  • Recurrent means the cancer came back after surgery
Read more

Sacituzumab tirumotecan (also known as sac-TMT) and pembrolizumab are the study medicines. Sac-TMT is an antibody drug conjugate (ADC). An ADC attaches to specific targets on cancer cells and delivers treatment to destroy those cells.

The goal of this study is to learn if people who receive sac-TMT with pembrolizumab live longer and without the cancer getting worse compared to people who receive pembrolizumab alone.

Read the detailed description

All participants undergo an initial Induction Phase of six cycles, each cycle consisting of pembrolizumab + carboplatin or cisplatin + paclitaxel or docetaxel. Each cycle is three weeks. Participants whose cancer does not progress enter the Maintenance Treatment Phase and are then randomly assigned to pembrolizumab + sac-TMT or pembrolizumab monotherapy. Participants whose cancer does progress will have the possibility to enter the Subsequent Treatment Phase and are then randomly assigned to pembrolizumab + sac-TMT or sac-TMT monotherapy.

Being tested
Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel, Sacituzumab Tirumotecan
Keywords
Programmed Cell Death-1 (PD1, PD-1), Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1), Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2), Trophoblast cell surface antigen 2 (TROP2)
Medical subject headings
Endometrial Neoplasms, Parkinson Disease 4, Autosomal Dominant Lewy Body

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PembrolizumabBiological

    Also called KEYTRUDA®, MK-3475, SCH 900475

    Intravenous (IV) Infusion

  • CarboplatinDrug

    During the Induction Phase, participants receive carboplatin AUC 5 (mg/mL/min) on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.

  • PaclitaxelDrug

    During the Induction Phase, participants receive paclitaxel 175 mg/m^2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.

  • DocetaxelDrug

    During the Induction Phase, participants may receive docetaxel (in place of paclitaxel) 75 mg/m^2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.

  • Sacituzumab TirumotecanBiological

    Also called sac-TMT, MK-2870, SKB264

    IV Infusion

  • CisplatinDrug

    During the Induction Phase, participants may receive cisplatin (in place of carboplatin) 75 mg/m^2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion

Study groups in NCT06952504
Study groupRoleWhat they receive
Maintenance Treatment Arm A: Pembrolizumab + Sacituzumab TirumotecanExperimentalDuring the Induction Phase, participants receive pembrolizumab 200 mg, carboplatin area under the curve (AUC) 5 (mg/mL/min) or cisplatin 75 mg/m^2, and paclitaxel 175 mg/m^2 or docetaxel 75 mg/m^2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months). During the Maintenance Treatment Phase, participants receive sac-TMT 4 mg/kg on Days 1, 15, and 29 of each 6-week cycle and pembrolizumab 400 mg on Day 1 of each 6-week cycle for up to 14 cycles (up to approximately 19 months).
Receives: Biological: Pembrolizumab; Drug: Carboplatin; Drug: Paclitaxel; Drug: Docetaxel; Biological: Sacituzumab Tirumotecan; Drug: Cisplatin
Maintenance Treatment Arm B: Pembrolizumab MonotherapyActive comparatorDuring the Induction Phase, participants receive pembrolizumab 200 mg, carboplatin AUC 5 (mg/mL/min) or cisplatin 75 mg/m^2, and paclitaxel 175 mg/m^2 or docetaxel 75 mg/m^2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months). During the Maintenance Treatment Phase, participants receive pembrolizumab 400 mg on Day 1 of each 6-week cycle for up to 14 cycles (up to approximately 19 months).
Receives: Biological: Pembrolizumab; Drug: Carboplatin; Drug: Paclitaxel; Drug: Docetaxel; Drug: Cisplatin
Subsequent Treatment Arm A: Pembrolizumab + Sacituzumab TirumotecanExperimentalDuring the Induction Phase, participants receive pembrolizumab 200 mg, carboplatin AUC 5 (mg/mL/min) or cisplatin 75 mg/m^2, and paclitaxel 175 mg/m^2 or docetaxel 75 mg/m^2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months). During the Subsequent Treatment Phase, participants receive sac-TMT 4 mg/kg on Days 1, 15, and 29 of each 6-week cycle until discontinuation criteria is met and pembrolizumab 400 mg on Day 1 of each 6-week cycle for up to 14 cycles (up to approximately 19 months).
Receives: Biological: Pembrolizumab; Drug: Carboplatin; Drug: Paclitaxel; Drug: Docetaxel; Biological: Sacituzumab Tirumotecan; Drug: Cisplatin
Subsequent Treatment Arm B: Sacituzumab Tirumotecan MonotherapyActive comparatorDuring the Induction Phase, participants receive pembrolizumab 200 mg, carboplatin AUC 5 (mg/mL/min) or cisplatin 75 mg/m^2, and paclitaxel 175 mg/m^2 or docetaxel 75 mg/m^2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months). During the Subsequent Treatment Phase, participants receive sac-TMT 4 mg/kg on Days 1, 15, and 29 of each 6-week cycle until discontinuation criteria is met.
Receives: Drug: Carboplatin; Drug: Paclitaxel; Drug: Docetaxel; Biological: Sacituzumab Tirumotecan; Drug: Cisplatin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Maintenance Treatment: Progression-Free Survival (PFS)

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as evaluated by the blinded independent central review (BICR). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD.

    Measured: Up to approximately 44 months

  2. Maintenance Treatment: Overall Survival (OS)

    OS is defined as time from randomization to death due to any cause.

    Measured: Up to approximately 54 months

Secondary outcomes (7)

  1. Maintenance Treatment: Progression-Free Survival 2 (PFS2) as Assessed by Investigator

    PFS2 is defined as the time from randomization to the documented subsequent objective disease progression after initiation of new anticancer therapy or death due to any cause, whichever occurs first. PFS2 as assessed by the investigator will be presented.

    Measured: Up to approximately 54 months

  2. Maintenance Treatment: Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Measured: Up to approximately 27 months

  3. Maintenance Treatment: Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Measured: Up to approximately 24 months

  4. Maintenance Treatment: Change from baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Mean Score

    EORTC QLQ-C30 is a 30-item scale to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7- point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score (Items 29 and 30) will be presented.

    Measured: Baseline and up to approximately 24 months

  5. Maintenance Treatment: Change from baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score

    EORTC QLQ-C30 is a 30-item scale to assess the overall quality of life of cancer patients. The physical functioning score is based on participant responses to questions scored on a 4-point scale (1 = 'Not at All' to 4 = 'Very Much'). Higher scores indicate better physical functioning. The change from baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) combined score will be presented.

    Measured: Baseline and up to approximately 24 months

  6. Maintenance Treatment: Change from baseline in EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score

    EORTC QLQ-C30 is a 30-item scale to assess the overall quality of life of cancer patients. The role functioning score is based on participant responses to questions scored on a 4-point scale (1 = 'Not at All' to 4 = 'Very Much'). Higher scores indicate better role functioning. The change from baseline in EORTC QLQ-C30 Role Functioning (Items 6 and 7) combined score will be presented.

    Measured: Baseline and up to approximately 24 months

  7. Maintenance Treatment: Change from baseline in EORTC QLQ-EN24 Symptom Score

    The EORTC QLQ-EN24 is a 24-item questionnaire developed to be used in conjunction with the EORTC-QLQ-C30 to assess the quality of life of endometrial cancer patients. Participant responses are scored on a 4-point scale (1=not at all to 4=very much). A higher score reflects greater symptom severity. The change from baseline in EORTC QLQ-EN24 back and pelvis pain score will be presented.

    Measured: Baseline and up to approximately 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 May 2025
  2. Study start22 May 2025
  3. Primary completion24 May 2032 (estimated)
  4. Study completion24 May 2032 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants are allocated to a single induction arm, then assigned randomly to either one of two maintenance treatment arms or one of two subsequent treatment arms.
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
1,123 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06952504
Sponsor's protocol ID
2870-033
Other IDs
2024-519331-42-00, U1111-1315-0794, GOG-3119, ENGOT-en29, TroFuse-033, jRCT2011250020
Acronym
TroFuse-033
Status last verified
Oct 2026
First submitted
23 Apr 2025
Last updated
13 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Pembrolizumab, Carboplatin and Paclitaxel in people with Endometrial Cancer, run by Merck Sharp & Dohme LLC at 268 sites in 34 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 268 sites in United States, China, Japan, Canada, Italy and 29 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Toll Free Number (1-888-577-8839, Trialsites@msd.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Maintenance Treatment: Progression-Free Survival (PFS) (time frame: Up to approximately 44 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06952504.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in